GLP-1 Overdose Sends 54-Year-Old Woman to Hospital
A 54-year-old North Carolina woman was recently hospitalized following an overdose of a compounded GLP-1 weight loss medication. Leslie Gammon sought treatment through a telehealth provider called Amble after previously using other weight loss options. She reported that her care consisted primarily of email communication and receiving medication vials by mail.
After expressing concern over a dosage increase from 8 units to 46 units, Gammon followed instructions she received from her provider. She ultimately administered 30 units of the compounded drug. Within two hours, she began experiencing severe, persistent vomiting. Her condition became so dire that she required three days of inpatient hospital care and remained unable to keep solid food down for an additional month. Medical staff confirmed she suffered a GLP-1 overdose, noting that the prescribed 46-unit dose was nearly five times the appropriate amount.
Dr. Fatima Syed of Duke Health points to a critical distinction in the market. While brand-name options like Ozempic, Wegovy, and Mounjaro undergo strict FDA review, compounded versions provided by some telehealth firms do not face the same oversight. These custom-made drugs are often cheaper, which attracts patients, but the safety risks remain a concern for medical professionals.
Gammon, who has since ceased all use of GLP-1 medications, faced a $9,000 hospital bill for her recovery. She stated that the provider, Amble, has not responded to her attempts to contact them regarding the incident. This case highlights the risks associated with the rapid expansion of telehealth prescription models for injectable weight loss drugs.